InventisBio Co., Ltd

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-02-26
Last Posted Date
2024-02-26
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
160
Registration Number
NCT06278350
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-01-31
Last Posted Date
2024-02-01
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
8
Registration Number
NCT06233916
Locations
🇨🇳

beijing Gobroad Boren Hospital, Beijing, China

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-10-27
Last Posted Date
2024-10-15
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
45
Registration Number
NCT06105255
Locations
🇨🇳

Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-12-27
Last Posted Date
2024-08-15
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
80
Registration Number
NCT05665699
Locations
🇺🇸

Site Center, Bellevue, Washington, United States

🇺🇸

Study Center, Morgantown, West Virginia, United States

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-08-17
Last Posted Date
2024-10-14
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
121
Registration Number
NCT05504083
Locations
🇨🇳

Inner Mongolia Baogang Hospital, Baotou, China

🇨🇳

Beijing Chao-yang Hospital, Capital Medical University, Beijing, China

🇨🇳

Peking Union Medical College Hospital, Beijing, China

and more 21 locations

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2022-08-08
Last Posted Date
2024-10-15
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
22
Registration Number
NCT05492045
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

🇨🇳

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China

Study to Evaluate D-1553 in Subjects With Lung Cancer

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-05-20
Last Posted Date
2024-10-14
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
225
Registration Number
NCT05383898
Locations
🇨🇳

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China

🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-05-18
Last Posted Date
2024-10-14
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
92
Registration Number
NCT05379946
Locations
🇨🇳

Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China

Evaluation of PK and Safety of D-0120 and Allopurinol

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-05-04
Last Posted Date
2023-03-01
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
20
Registration Number
NCT05360628
Locations
🇺🇸

Spaulding Clinical, West Bend, Wisconsin, United States

Study in Healthy Adult Female Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-04-21
Last Posted Date
2023-04-06
Lead Sponsor
InventisBio Co., Ltd
Target Recruit Count
8
Registration Number
NCT05339633
Locations
🇺🇸

Site Location, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath